| Literature DB >> 31684040 |
Abstract
The benzodiazepine class of drugs are characterised by a readily electrochemically reducible azomethine group. A number are also substituted by other electrochemically active nitro, N-oxide, and carbonyl groups, making them readily accessible to electrochemical determination. Techniques such as polarography, voltammetry, and potentiometry have been employed for pharmaceutical and biomedical samples, requiring little sample preparation. This review describes current developments in the design and applications of electrochemical-based approaches for the determination of the benzodiazepine class of drugs form their introduction in the early 1960s to 2019. Throughout this period, state-of-the-art electroanalytical techniques have been reported for their determination. Polarography was first employed focused on mechanistic investigations. Subsequent studies showed the adsorption of many the benzodiazepines at Hg electrodes allowed for the highly sensitive technique of adsorptive stripping voltammetry to be employed. The development and introduction of other working electrode materials such as carbon led to techniques such as voltammetry to become commonly reported, and the modification of these electrodes has now become the most commonly employed approach using molecularly imprinting and nanotechnology.Entities:
Keywords: analysis; benzodiazepine; biomedical; electrochemistry; forensic; polarography; review; voltammetry
Mesh:
Substances:
Year: 2019 PMID: 31684040 PMCID: PMC6955736 DOI: 10.3390/bios9040130
Source DB: PubMed Journal: Biosensors (Basel) ISSN: 2079-6374
Pre-2006 polarographic and voltammetric methods for the determination of benzodiazepines at mercury-based electrodes.
| Benzodiazepine | Electrode Material | Linear Range (M) | Detection Limit (M) | Electrolyte | Waveform and Technique | Sample (s) | Reference |
|---|---|---|---|---|---|---|---|
| 7-acetamido-nitrazepam, dimethyl-diazepam, chlordiazepoxide lactam, 7-amino-diazepam | Dropping mercury electrode | - | - | Britton-Robinson buffer, 0.04 M, plus 0.1 M NaOH to obtain desired pH | DPP | Mechanistic study | [ |
| Bromazepam, clonazepam, diazepam, flurazepam, midazolam, and medazepam | Hanging mercury drop electrode | Clonazepam 1 × 10−7 to 1 × 10−5, bromazepam 1 × 10−7 to 1 × 10−5, midazolam 1 × 10−7 to 1 × 10−5, diazepam 1 × 10−7 to 1 × 10−5, SWCSV clonazepam 1 × 10−8 to 8 × 10−8¸ bromazepam 1 × 10−8 to 8 × 10−8, midazolam 1 × 10−8 to 8 × 10−8, diazepam 1 × 10−8 to 8 × 10–8, medazepam 1 × 10−8 to 8 × 10−8 | SWV, clonazepam 1.3 × 10−8, bromazepam 1.2 × 10−8, midazolam 1.6 × 10−8, diazepam 1.0 × 10−8, SWCSV clonazepam 2.9 × 10−9, bromazepam 2.6 × 10−9, midazolam 2.0 × 10−9, diazepam 2.0 × 10−9, medazepam 1.3 × 10−9, flurazepam 2.5 × 10−9 | 0.10 M KNO3, and Britton–Robinson pH 6.0 buffer | SWV and SWCSV | Tablets | [ |
| Diazepam, oxazepam nitrazepam, and flurazepam | Dropping mercury electrode | 2 × 10−7 to 10 × 10−7 | 2 × 10−7 | 0.2 M acetate pH 4.8 buffer | DPP, DC polarography | Rabbit urine | [ |
| Midazolam | Static mercury drop electrode | 3.6–36 µM | 100 pM | Acetate pH ca. 4.8 buffer | SWAdSV, NPV | - | [ |
| Midazolam | Static mercury drop electrode | - | - | 0.1 M acetate pH 4.8 buffer | NPV | Mechanistic study | [ |
| Midazolam | Hanging mercury drop electrode | 1.9 × 10−6 to 10−9 | Britton-Robinson pH 5.00 buffer | AdSV | Pharmaceutical formulations | [ | |
| Midazolam and metabolites (α-hydroxy-midazolam, 3-hydroxy-midazolam and α,3-hydroxy-midazolam) | Static mercury drop electrode | 10−4 to 10−7 | 6 × 10−8 | Sulphuric acid 1.0 M | DPP | - | [ |
| Camazepam and bromazepam | Hanging Hg drop electrode | Camazepam 1 × 10−9 to 9 × 10−9, bromazepam 1 × 10−8 × 10−8, 270 s at −0.60 V | Camazepam 20 ng/mL and bromazepam 200 ng/mL | DPAdSV | Human serum after isolation with Sep-Pak CI8 cartridges | [ | |
| Flurazepam and metabolites | Dropping mercury electrode | Three orders of magnitude | 5 × 10−8 | Formate pH 4 buffer | DPP | 15 mg and 30 mg capsules | [ |
| Loprazolam mesilate | Static mercury drop electrode | 2.5 × 10−10 to 8.0 × 10−9 | 2.5 × 10−10 | 0.04 M ammonium chloride pH 4.0 | SWAdCSV | - | [ |
| Loprazolam mesilate | Dropping mercury electrode and a static mercury electrode | - | - | DC, AC, normal and inverse pulse polarography, CV, and controlled potential coulometry | Mechanistic study | [ | |
| Oxazepam and lorazepam | Dropping and hanging mercury electrodes | 1.0 × 10−5 to 1.5 × 10−7 for oxazepam and 2.5 × 10−7 to 2.0 × 10−7 for lorazepam | 1.25 × 10−7 for oxazepam, | Britton-Robinson buffer | DC and AC polarography, CV, DPP, rotating disk voltammetry | Oxazepam in serepax, serenal tablets, and serenid forete capsule; lorazepam in Larpose, activan, trapex tablets | [ |
| Oxazepam, lorazepam, and quinazolinecarboxaldehyde | Dropping and hanging mercury electrodes | 10−5 to 10−3 in 10% DMSO/water, 10−5 to 10−4 in water | - | 0.1 M tetraethyl ammonium perchlorate in 90% DMSO/10% water | polarography | Serenid-D and Ativan tablets | [ |
| Oxazepam | Forced drop mercury electrode | 1 × 10−5 to 1 × 10−2 | - | 0.1 M aqueous tetraethyl ammonium iodide | polarography | 10 mg tablets | [ |
| Halazepam | Dropping and hanging mercury electrodes | 1 × 10−8 to 1.6 × 10−7 | 25 ng/mL | 0.04 M acetate pH 4.8 buffer | DPAdSV −0.5 V | Human serum and urine | [ |
| Bromazepam and | Dropping mercury electrode | 5–500 ng/mL | 10–20 ng/mL | 1 M phosphate pH 4.0 and pH 7.0 buffers containing 0.005% methoxypolyethylene glycol 550 | DPP | Human blood | [ |
| Flunitrazepam | Hanging mercury drop electrode | 0.6 × 10−8 to 3.1 × 10−7 | 9.0 × 10−10 | 0.02 M Britton-Robinson pH 10 buffer | Staircase voltammetry and DPAdSV | Urine, following extraction with diethyl ether | [ |
| Flunitrazepam | Dropping Hg electrode | 1.5 × 10−5 to 2.5 × 10−7 | - | 0.2 M boric acid, 0.05 M citric acid, and 0.1 M trisodium orthophosphate pH 4 buffer, containing 0.2% Triton X-100 | DPP | Rohypnol tablets | [ |
| Clonazepam | Hanging mercury drop electrode | Up to 550 ng/mL | 10 ng/mL | 0.025 M carbonate pH 10.0 buffer | DPAdSV | Urine, after extraction | [ |
| Nitrazepam | Nafion-coated Hg film glassy carbon electrode | Up to 7 × 10−6 | - | Acetate pH 4.6 buffer | DPAdSV | - | [ |
| Nitrazepam | Dropping mercury electrode | - | 0.27 µg/mL | McIlvaine pH 3.1 buffer | Polarography | Tablets: Nitravet, Nirven, Sedamon, Hypnotex, Restorem, and Capsule: Hypnotex | [ |
| Nitrazepam | Hanging mercury drop | 0.5–80 µg/mL in serum by polarography | 0.5 µg/mL | Phosphate pH 6.9 buffer | Polarography, CV, chronopotentiometry, controlled coulometry | Serum (without dilution or pre-treatment) | [ |
| Nitrazepam, flunitrazepam, and clonazepam as their 2-amino-5-nitrobenzophenones acid hydrolysis products | Glassy carbon electrode | - | - | Polarography, 0.11 M pyridine, and 0.12 M formic acid pH 4.5, CV formate buffer | CV, polarography | - | [ |
| Camazepam, oxazepam, and temazepam | Hanging mercury electrode | Oxazepam 2.8 × 10−8 to 4.0 × 10−7 | Oxazepam 3.6 × 10–10 | 0.008 M Britton–Robinson pH 2.0 buffer | DPAdSV | Human serum albumin | [ |
| Temazepam | Hanging mercury electrode | 10–100 µg/mL | Acetate pH 4.7 buffer solution containing 10% dimethylfonnamide | Polarography and DPP | Soft gelatine capsule formulations after enzyme dissolution | [ | |
| Pivazepam | Hanging mercury electrode | 10−7 to 10−5 | Urine 15 ng/mL, following diethyl ether extraction | DPAdSV 0.1 M McIlvaine pH 4.0 buffer, 10% methanol, DPP 0.04 M Britton-Robinson pH 5 buffer | DPP, DPAdSV | Pharmaceutical tablet formulations and urine | [ |
| Chlordiazepoxide, nitrazepam, clonazepam, flunitrazepam, oxazepam, lorazepam, diazepam, bromazepam, prazepam, flurazepam, -otassium chlorazepate, and medazepam | Dropping mercury electrode | - | - | Britton–Robinson pH 4.0 and pH 12.0 buffers | Polarography | Mechanistic studies, hydrolysis products investigated | [ |
| chlorazepate | Dropping Hg electrode | 10−7 to 3 × 10−5 | ca. 10−7 | Britton-Robinson pH 4 buffer | Cathode ray polarography | Urine after adjustment to pH 9 and liquid-liquid extraction with ethyl acetate | [ |
| Oxazepam | Dropping Hg electrode | - | - | 0.1 M HCl/20% methanol | Polarography | Unsuccessful for the direct determination of pharmaceutical formulation | [ |
| Diazepam | Dropping mercury electrode | 2 × 10−6 to 10−3 | - | Britton-Robinson pH 1.81 buffer—0% methanol | DCP, CV, coulometry | Mechanism study | [ |
| Diazepam | Dropping mercury electrode | Alternating current polarography 17.4–167 µM; DPP 4.8–96 µM | - | 2 M acetate pH 4.6 solution | DCP, DPP, and alternating current polarography | 10 mg tablets | [ |
| Diazepam | Hanging mercury drop electrode | - | 1 µg/mL | 0.1 M KCl solution in 50% ethanol | DPP | Forensic investigations of Toddy (fermented sap or exudate of date, Palmyra, coconut, sago, etc.) | [ |
| Diazepam | Hanging mercury drop electrode | 5.6 × 10−8 to 8.8 × 10−6 and 8.8 × 10−6 to 2.0 × 10−4 | 9.6 × 10−9 | 0.20 M pH 4.7 acetate buffer, −2.0 × 10−2 M K2S2O8 | Polarographic parallel catalytic wave of persulfate | Tablets | [ |
| Mexazolam | Hanging mercury drop electrode | Up to 13 µg/mL | 80 ng/mL | DPP | [ | ||
| Bentazepam | Hanging mercury drop electrode | 1.9–9.4 ng/mL by DPAdSV | 2.7 ng/mL in urine by DPAdSV; 3.1 × 10−9 M by DPP | DPP in 0.04 M Britton-Robinson pH 9 buffer; DPAdSV in 0.08 M phosphate pH 8.0 buffer | DPP, DPAdSV | Tiadipona tablets by DPP and in urine by DPAdSV | [ |
| Chlordiazepoxide | Hanging mercury drop electrode | 5 × 10−9 to 2 × 10−7 in human serum by SWAdCSV | 4.4 × 10−10 and 6.6 × 10−10 for pharmaceutical and human serum, respectively, by SWAdCSV | Britton-Robinson pH 8 buffer | Polarography, CV, controlled potential coulometry and SWAdCSV | Bulk form, Librax tablets and human serum (after protein precipitation with ethanol and centrifugation) | [ |
| Chlordiazepoxide | Static mercury drop electrode | - | - | 0.1 M acetate buffer | SWAdCSV | Synthetic solutions measured in the presence of chloramphenicol, metronidazole, oxytetracycline, cephalothin, and trimethoprim | [ |
| Chlordiazepoxide | Hanging mercury drop electrode | Quasilinear over the ranges: 3.20 × 10−8 to 1.60 × 10−7; 1.60 × 10−7 to 1.44 × 10−6; 1.44 × 10−6 to 1.44 × 10−5 | 9 × 10−9 | 0.12 M NH3/NH4Cl pH 10.2/0.016 M K2S2O6 | Polarography | - | [ |
| Chlordiazepoxide | Hanging mercury drop electrode | 0.8 to 11 × 10−8 | 0.9 × 10−9 | Britton-Robinson pH 6.8 buffer | DPAdCSV | Human serum, after solid phase extraction with Sep-Pak C18 cartridge | [ |
| Chlordiazepoxide | Dropping Hg electrode | 2.5 × 10−6 to 10−3 | 2.5 × 10−6 | 0.1 M sulphuric acid | Polarography, CV, coulometry | Alpoxide and Prodixamon tablets, serum | [ |
| Chlordiazepoxide and metabolites: | Dropping Hg electrode | 0.05–1.0 µg/mL | Chlordiazepoxide and its desmethyl metabolite approximately 0.05 µg/mL for plasma; demoxepam, 0.10 µg/mL | 0.1 N sulphuric acid | DPP | Plasma after 30 mg dose extracted with diethyl ether at pH 9 and analytes isolation by thin layer chromatography | [ |
| Chlordiazepoxide and diazepam | Dropping Hg electrode | - | - | 0.1 M sulphuric acid | Automated polarography | Alpoxide and Vival tablets | [ |
| Lorazepam | Hanging mercury drop electrode | 0.05–1.15 µg/mL | 0.019 µg/mL | Britton-Robinson pH 2 buffer | CAdSV | Urine, plasma, Chemidarou and Zahrav tablets | [ |
| Lorazepam | Hanging mercury drop electrode | 15 ng/mL in urine | Britton-Robinson pH 2 buffer | DPAdSV | Human urine | [ | |
| Nimetazepam | Dropping Hg electrode | 30–150 µg/mL | 30 µg/mL | Britton–Robinson pH 3.8 buffer, 50% methanol | Polarography, 0.0 to −0.7 V | Serum and whole blood after extraction with ethyl acetate/toluene 1:1 | [ |
| Pinazepam and BrTDO | Hanging mercury drop electrode | Pinazepam 2.8 × 10−10, BrTDO 2.2 × 10−10 | 0.04 M Britton-Robinson buffers pH 4 and pH 5 | DPAdSV | Human serum | [ | |
| Pinazepam, camazepam, bromazepam, and BrTDO | Hanging mercury drop electrode | Pinazepam 100–700 ng/mL, camazepam 100–1000 ng/mL, bromazepam 100–1000 ng/mL, and BrTDO 100–1000 ng/mL | Pinazepam 15 ng/mL, camazepam 10 ng/mL, bromazepam 20 ng/mL, and BrTDO 20 ng/mL | Britton–Robinson pH 4 buffer for Pinazepam and pH 5 for bromazepam and BrTDO; Acetate pH 5 buffer for camazepam | DPAdSV | Urine after solid-phase extraction with C18 Sep-pak | [ |
| Timelotem | Dropping mercury electrode | - | 2.5 × 10−6 | Britton–Robinson buffers containing 10% methanol | - | - | [ |
| Tetrazepam, nortetrazepam, and menitrazepam | Hanging and dropping mercury electrodes | 5 × 10−7 to 5 × 10−6 tetrazepam | 10−7 | 0.1 M sulphuric acid, containing 1% dimethylacetamide | Polarography and DPP | - | [ |
| Clotiazepam | Dropping mercury electrode | 6.5 × 10−7 to 1.10 × 10−5 | - | 0.1 M sulphuric acid | Polarography and DPP | Distensan tablets | [ |
| Estazolam | Dropping mercury electrode | 1 × 10−7 to 9.0 × 10−6 | 5 × 10−8 | 0.1 M NH3–NH4Cl pH 9.2 buffer | Polarography | - | [ |
| Camazepam | Dropping mercury electrode | 1.3 × 10−6 to 1.0 × 10−5 by DPP | 1.7 × 10−8 by DPP | 0.2 M phosphate pH 6.0 buffer | Current sampled polarography, CV, and DPP | Urine, with and without solid phase extraction (Sep-Pak C18) and Albego dragees (sugar-coated) 10 and 20 mg tablets | [ |
| Metaclazepam | DC tast, DPP and DPAdSV at dropping mercury, hanging mercury electrodes; CV at hanging mercury electrode; coulometry at mercury pool | 1.8 × 10−9 to 3.2 × 10−7 by DPAdSV | 4.4 × 10−10 by DPAdSV | Polarography: Britton-Robinson buffer; coulometry: 4% ethanol/Britton-Robinson buffer | DC tast and DPP, CV, microcoulometry, and DPAdSV | Human urine, 2 mL diluted with 1 mL of 0.04 M pH 9.2 borate buffer; extracted with 1 mL of diethyl ether Evaporated to dryness and reconstituted in ethanol; diluted with 25 mL 0.04 M Britton-Robinson buffer pH 9.1 | [ |
| Triazolam and clotiazepam | Hanging mercury drop electrode | Up to 2.2 × 10−7 for both triazolam and clotiazepam | 6 × 10−10 for triazolam and clotiazepam with accumulation times of 4 and 10 min by DPAdSV | 10−2 M carbonate pH 10 buffer | DPAdSV | - | [ |
| Diazepam and nitrazepam | Hanging mercury drop electrode | 1 × 10−9 to 1 × 10−6 | - | Acetate pH 4.6 buffer | DPAdSV | - | [ |
Pre-2006 voltammetric methods for the determination of benzodiazepines at carbon-based electrodes.
| Benzodiazepine | Electrode Material | Linear Range (M) | Detection Limit (M) | Electrolyte | Waveform and Technique | Sample (s) | Reference |
|---|---|---|---|---|---|---|---|
| Diazepam, temazepam, and oxazepam | Modified carbon-paste electrodes | Diazepam 0.025–3.0 µg/mL, Temazepam 0.025–0.8 µg/mL, oxazepam 0.025–1.0 µg/mL | Diazepam 0.021 µg/mL, temazepam 0.021 µg/mL, oxazepam 0.012 µg/mL | Britton-Robinson buffer 0.1 M | DPV | Plasma and urine, following SPE | [ |
| Loprazolam | Carbon-paste electrode | 1.5 × 10−7 | Britton-Robinson pH 6.3 buffer | DPV | Somnovit (1 mg) tablets | [ | |
| Flunitrazepam | Bentonite-modified carbon paste | 0.2–4.0 µg/mL | 0.04 µg/mL | Accumulation media: pH 3.8, adjusted with either nitric acid or potassium hydroxide; measurement media: 0.5 M potassium nitrate pH 3.8 | DPV, adsorption at open circuit | Serum and urine | [ |
| Olanzapine | Glassy carbon electrode | 6.2–50.0 µg/mL | 3 µg/mL | 0.25 M phosphate pH 2.5 buffer | LSV | Ziprexa tablets | [ |
| Bentazepam | C18(Bonda pack, 50% | 0.5–2 µg/mL | 0.5 µg/mL | Accumulation media: 0.04 M Britton-Robinson pH 6 buffer; measurement: 0.3 M phosphate pH 2 buffer | DPAdSV, open circuit accumulation, measurement DPV scan 0 to +1.3 V | Human urine | [ |
| Olanzapine | Glassy carbon electrode | DPV and OSWV 7.00 × 10−5 to 1.00 × 10−3 | DPV 6.79 × 10−6, OSWV 6.91 × 10−6 | Britton-Robinson pH 3.24 buffer | CV, DPV, and OSWV | 10 mg Zyprexa tablets | [ |
| Nitrazepam and flunitrazepam | Glassy carbon electrode | 5.6–28.1 pg/mL and 6.3–31.3 pg/mL for nitrazepam and flunitrazepam, respectively | 1.8 µg/mL and 1.3 µg/mL for nitrazepam and flunitrazepam, respectively | 0.1 M phosphate pH 7.0 buffer, containing 10% v/v methanol | Flow injection analysis, 4.0 mL/min, −0.9 V | Tablet formulations of nitrazepam and flunitrazepam | [ |
| Clonazepam | Glassy carbon electrode | 6.3–31.5 pg/mL | 3.3 µg/mL | 0.1 M phosphate buffer solution (pH 7.0) containing 10% | Flow injection analysis, 4.0 mL/min, −0.9 V | Tablet formulations and human urine | [ |
| Diazepam | Glassy carbon electrode | 1 × 10−3 to 1 × 10−4 | - | HCl–KCl pH 1 buffer containing 10% ethanol | CV | Tablets, capsules, injection, and syrup formulations | [ |
| Diazepam | Glassy carbon electrode | 0.158–9.48 µM | - | Solution of 0.1 M KCl and 0.01 M pH 4.0 potassium biphthalate buffer | Pulsed rotation voltammetry | - | [ |
| Chlordiazepoxide, medazepam, nitrazepam, amino-nitrazepam, lorazepam, and flurazepam | Glassy carbon electrode | - | - | Britton–Robinson pH 4 buffer, containing 10% methanol | Differential pulse flow injection analysis +1.2 V (no oxidation signal seen for nitrazepam) | Tablets | [ |
| Tifluadom | C18 µBondapak-modified carbon-paste electrode | 2.2 × 10−7 to 4.5 × 10−6 | 1.3 × 10−6 in urine, 1.3 × 10−7 in buffer | Britton-Robinson pH 6 buffer | CV | Urine | [ |
| Alprazolam | Glassy carbon electrode and static Hg drop electrode | 2.5 × 10−7 to 3.25 × 10−5 | - | Britton-Robinson pH 9 buffer | Differential pulse polarography | - | [ |
| Flurazepam, oxazepam, medazepam, lorazepam, flunitrazepam, prazepam, potassium chlorazepate, nitrazepam, and amino-nitrazepam | Wall-jet glassy carbon electrode | - | - | Britton-Robinson pH 4 buffer, containing 10% methanol | Differential pulse flow injection analysis +1.2 V | Tablets | [ |
| Flurazepam, chlordiazepoxide, oxazepam, lorazepam, potassium chlorazepate, nitrazepam, flunitrazepam, prazepam, diazepamm and medazepam, and some of their metabolites | Wall-jet glassy carbon electrode | 5 × 10−5 to 2 × 10−4 | - | 0.01 M sodium hydroxide | Differential pulse flow injection analysis +1.2 V | - | [ |
| Quetiapine fumarate and olanzapine | Glassy carbon electrode | Quetiapine 3 × 10−8 to 4 × 10−6, and quetiapine fumarate 2 × 10−8 to 5 × 10−6 | 1 × 10−8 for both | Britton-Robinson pH 2 buffer | Differential pulse voltammetry | Tablets (Zyprexa and Seroquel), urine, and serum | [ |
Note: Cathodic adsorptive stripping voltammetry (CAdSV), differential pulse adsorptive stripping voltammetry (DPAdSV), differential pulse polarography (DPP), square wave adsorptive stripping voltammetry (SWAdSV), normal pulse voltammetry (NPV), linear sweep voltammetry (LSV), Osteryoung square wave voltammetry (OSWV), cyclic voltammetry (CV), and linear sweep voltammetry (LSV).
Ion-selective electrodes for the determination of benzodiazepines.
| Benzodiazepine | Electrode Material | Linear Range (M) | Detection Limit (M) | Electrolyte | Sample (s) | Reference | |
|---|---|---|---|---|---|---|---|
| Diazepam, bromazepam, and clonazepam | PVC-based ion-selective electrodes | 2.5 × 10−6 to 10−4, 5 × 10−6 to 10−4, and 2.5 × 10−4 to 10−6 for diazepam, bromazepam, and clonazepam, respectively | 2, 0.307, and 0.9 µM, for diazepam, bromazepam, and clonazepam, respectively | Potentiometric, 10−4 M HCl | Ion-selective electrodes | Urine, Vallium, Rivotril, and Calmepam tablets | [ |
| Bromazepam | Bromazepam-phosphotungestiate ion association complex in poly(vinyl chloride) membrane | 1 × 10−2 to 1 × 10−4 | 3 × 10−5 | Potentiometric | Ion-selective electrodes | Lextonil, Neoopt, and Calmepam tablets | [ |
| Diazepam, bromazepam, and clonazepam | PVC solid contact ion-selective electrodes | 0.29–71.20, 0.79–31.62, and 0.32–31.57 µg/mL for diazepam, bromazepam, and clonazepam, respectively | 0.71, 0.79, and 0.79 µg/mL for diazepam, bromazepam, and clonazepam, respectively | Potentiometric, 10−4 M HCL | Ion-selective electrodes | Vallium, Rivotril, and Calmepam tablets | [ |
Scheme 1Proposed voltammetric redox behavior of nitrazepam at a screen-printed carbon electrode.
Figure 1Gas chromatography of clonazepam and possible base hydrolysis product. (a) Full scan chromatogram; (b) hydrolysis mass spectrum (retention time 24.1 min); (c) clonazepam mass spectrum (retention time 26.2 min); and (d) cyclic voltammogram obtained in pH 11 phosphate buffer for a 1 mM clonazepam solution [116].